课题基金 / 基金详情

Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms

Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms
使用新型疫苗递送平台增强 B 细胞针对 HIV-1 的免疫力
批准号:
8310163
负责人:
Michael W Cho
金额:
$124.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-01 至 2015-07-31

项目摘要

项目成果

Michael W Cho的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):全球迫切需要研制一种具有保护性的艾滋病疫苗。中和抗体(nab)可以有效预防HIV-1感染。虽然激发具有广泛交叉反应的nab一直是一个重大的科学挑战,但我们最近产生了一种含有gp41的膜近端外区(MPER)的迷你蛋白,可以引发具有显著宽度的nab。本提案的主要目标是开发能够增强B细胞免疫反应的新型疫苗递送平台。
英文摘要
DESCRIPTION (provided by applicant): There is a global urgency to develop a protective AIDS vaccine. Neutralizing antibodies (Nabs) can provide effective prophylaxis against HIV-1 infections. Although eliciting Nabs that are broadly cross-reactive has long been a major scientific challenge, we have recently generated a mini-protein containing the membrane-proximal external region (MPER) of gp41 that can elicit Nabs with significant breadth. The primary objective of this proposal is to develop novel vaccine delivery platforms that can enhance B cell immune responses. The underlying hypothesis behind this proposal is that a polymeric antigen containing many copies of the same target epitope in a repetitive, well-defined lattice (multivalent) can elicit a superior B cell immune response than a monomeric antigen (monovalent) because of its potential to (1) induce both T cell-independent (Tl) and -dependent (TD) B cell immunity; (2) enhance B cell activation and maturation; and (3) activate a greater diversity of B cell subsets. To test this hypothesis, we will develop novel vaccine delivery platforms based on nanostructures designed to present multivalent forms of immunogens and costimulatory molecules to B cells and to facilitate targeted delivery of antigens to dendritic cells and macrophages. Successful completion of the proposed studies would represent a major advancement towards developing a protective AIDS vaccine. The proposed research Program consists of two Projects and two Cores: The role of Project 1 is to develop vaccine delivery platforms. The role of Project 2 is to evaluate B cell immune responses against gp41- MPER in great detail. The Administrative Core is responsible for providing the organizational management and maintaining infrastructure to support the fiscal monitoring. The Protein Production Core is responsible for producing and providing high quality antigens and costimulatory molecules to Projects 1 and 2. This is a highly collaborative program project of seven key investigators from five institutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Induction of bnAbs against HIV-1 gp41.
  • 批准号:
    10603692
  • 项目类别:
  • 资助金额:
    $29.73万
  • 财政年份:
    2022
  • 负责人:
    Michael W Cho
  • 依托单位:
Development of a vaccine strategy using antibody-complexed antigens
  • 批准号:
    9161293
  • 项目类别:
  • 资助金额:
    $22.04万
  • 财政年份:
    2016
  • 负责人:
    Michael W Cho
  • 依托单位:
Vaccines Against Antigenically Variable Viruses Symposium
  • 批准号:
    9065323
  • 项目类别:
  • 资助金额:
    $0.75万
  • 财政年份:
    2015
  • 负责人:
    Michael W Cho
  • 依托单位:
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms
  • 批准号:
    8514495
  • 项目类别:
  • 资助金额:
    $128.13万
  • 财政年份:
    2010
  • 负责人:
    Michael W Cho
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究